PhD position translational tumor immunology (m/f/d)
Pathologie
38.5 Stunden
auf 12 Monate befristet
ab 01.05.2023
Eingruppierung gemäß
TV-L
Bewerbungsfrist 31.03.2023
Uniklinikum Erlangen
Pathologisches Institut
Dr. med. Markus Eckstein
Krankenhausstraße 8/10
91054 Erlangen
Pathologisches Institut
Dr. med. Markus Eckstein
Krankenhausstraße 8/10
91054 Erlangen
Ihre Ansprechperson bei Fragen
Dr. med. Markus Eckstein
AG-Leitung
Telefon: 09131 85-47792
Dr. med. Markus Eckstein
AG-Leitung
Telefon: 09131 85-47792
PhD position translational tumor immunology (m/f/d)
Veröffentlicht seit: 17.02.2023Job-Nr.: 5351
Dr. med. Markus Eckstein
AG-Leitung
Telefon: 09131 85-47792
AG-Leitung
Telefon: 09131 85-47792
Uniklinikum Erlangen
Pathologisches Institut
Dr. med. Markus Eckstein
Krankenhausstraße 8/10
91054 Erlangen
Pathologisches Institut
Dr. med. Markus Eckstein
Krankenhausstraße 8/10
91054 Erlangen
PhD position translational tumor immunology (m/f/d)
Veröffentlicht seit: 17.02.2023
Job-Nr.: 5351
Dr. med. Markus Eckstein
AG-Leitung
Telefon: 09131 85-47792
Veröffentlicht seit: 17.02.2023
Job-Nr.: 5351
Uniklinikum Erlangen
Pathologisches Institut
Dr. med. Markus Eckstein
Krankenhausstraße 8/10
91054 Erlangen
Ihre Ansprechperson bei FragenPathologisches Institut
Dr. med. Markus Eckstein
Krankenhausstraße 8/10
91054 Erlangen
Dr. med. Markus Eckstein
AG-Leitung
Telefon: 09131 85-47792
Klingt spannend?
Das sind wir:
Group of translational tumor immunology, Institute of Pathology.
The Eckstein lab (junior clinician scientist group):
We are currently 2 postdocs, 1 PhD student, and 2 technicians plus multiple MD, DMD and Master students. The lab is very international and interdisciplinary working on cancer biology, tumor immunology and development of urothelial cancer utilizing molecular and cell biology techniques, high throughput genetic analysis tools and bioinformatical data mining mainly using human patient tissues.
Dr. Eckstein has published > 100 manuscripts (>15 as senior author) in peer-reviewed scientific journals with > 1,800 total citations and an h-index of 23 (i10-index 57). He published in a large variety of high impact factor (IF) translational cancer research journals as senior author (IF > 10: Eur Urology, Cancer Research, Clinical Cancer Research, Eur J Cancer, JITC). In addition, the group is highly engaged in collaborations and contributed to publications in journals such as Nature Medicine and Annals of Oncology.
The project is part of the Interdisciplinary Center for Clinical Research (IZKF, in collaboration with Professor Felix Engel, Department of Nephropathology).Project description: Platinum-based chemotherapy, targeted chemotherapy and immune checkpoint inhibitors are approved for clinical handling of locally advanced (la) and metastatic (m) urothelial carcinoma (UC). Yet, overall response rates for these therapies are limited (~20%), patients often progress rapidly, and molecular insights in processes driving therapy resistance are scarce. TCGA data analysis suggests that fatty acid (FA) metabolism and ferroptosis are deregulated in UC contributing to chemoresistance. Overall aim of the here proposed project is to expand our already initiated living patient-derived laUC/mUC biobank to identify novel predictive biomarkers for laUC/mUC patients eligible for either chemo- or immunotherapy as well as to utilize a high throughput zebrafish platform to elucidate mechanism underlying chemo- and immunotherapy resistance and to predict therapy outcome.
Die Aufgaben
- Aim 1: Expanding our existing patient-derived living laUC/mUC biobank and identification of predictive biomarkers in regards to therapy resistance
- Aim 2: Evaluating the therapeutic response of patient-derived UC cells in a zebrafish model
- Aim 3: Determining the effect of ferroptosis induction and/or FA metabolism alteration on UC treatment resistance utilizing a novel zebrafish model
- Aim 4: Assessing the role of potential biomarkers in chemo- and immunotherapy resistance.
Main tasks of the translational tumor immunology will be in depth analysis of organoids, human tissues and cell lines with high throughput bulk and spatial (sequencing) methods to unravel immunotherapy resistance mechanisms of la/mUC. Main tasks will include:
- Generation of organoids and tissue banking
- Development and application of bioinformatical data analysis pipelines for several methods like mutational sequencing, RNA sequencing, spatial transcriptomics and proteomics
- Development and application of bioinformatical and artificial intelligence- based image analysis tools for spatial transcriptomics and proteomics
It is expected that the candidates have experience in tissue banking, tissue and cell line processing (incl. RNA- and DNA as well as protein isolation), immunohistochemistry/immunofluorescence, digital image analysis, analytics of standard sequencing methodologies and bioinformatical data analysis with standard tools and programming languages such as R and python.
Das Know-how dafür
- Diplom or Master in Biology, Chemistry, Biochemistry, Molecular Medicine, Bioinformatics or similar disciplines
- Very good English speaking and writing skills
Zusätzlich von Vorteil
- Experience with tissue banking and processing.
- Experience with digital image analysis.
- Experience with bioinformatical data analysis of (spatial) sequencing data and proteomic data with standard tools and programming languages such as R and python.